BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.835 -0.185 (-2.31%)

Delayed Quote Updated: 11:55 AM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

BioCryst Eyes $1B Rare-Disease Future Through External Innovation ↗

September 18, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief...

Via MarketBeat

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen ↗

August 21, 2026

Via Chartmill

BioCryst (BCRX) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

ORLADEYO revenue hit $158.2M with 10% growth as pediatric launch exceeded expectations.

Via The Motley Fool

Topics Earnings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Surges on Q2 Earnings Beat ↗

August 05, 2026

Via Chartmill

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Q1 2026 Results: Revenue Beat, EPS Miss ↗

May 06, 2026

Via Chartmill

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗

February 26, 2026

Via Chartmill

BioCryst Pharmaceuticals Q2 Earnings Call Highlights ↗

August 05, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of...

Via MarketBeat

Topics Earnings

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

July 15, 2026

From BioCryst Pharmaceuticals, Inc.

Via GlobeNewswire

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

June 29, 2026

From BioCryst Pharmaceuticals, Inc.

Via GlobeNewswire

BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances ↗

June 06, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth...

Via MarketBeat

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗

December 12, 2025

Via Stocktwits

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗

October 14, 2025

Via Stocktwits

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings ↗

May 07, 2026

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.

Via Benzinga

BioCryst (BCRX) Q1 2026 Earnings Transcript ↗

May 06, 2026

BioCryst (BCRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 12, 2025

From Astria Therapeutics, Inc.

Via Business Wire

BioCryst To Acquire Astria Therapeutics In $700M Deal ↗

October 14, 2025

Via Stocktwits

BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

BioCryst (BCRX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Via Benzinga

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗

November 03, 2025

BioCryst Q3 2025 results: Earnings beat estimates with $0.06 EPS, but revenue of $159.4M missed forecasts. ORLADEYO sales grew 37%.

Via Chartmill

Topics Earnings

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

October 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

October 16, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗

October 14, 2025

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth.

Via Benzinga

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

October 14, 2025

From Astria Therapeutics, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.